We are live on ! Find out more
PHAR

Pharming Group
PHAR

2 hedge funds and large institutions have $266K invested in Pharming Group in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

10% less capital invested

Capital invested by funds: $296K → $266K (-$29.2K)

33% less funds holding

Funds holding: 3 → 2 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$35.5K

Top Sellers

Rank Fund Capital Flow
1
BCI
Brinker Capital Investments
Pennsylvania
-$134K
2
OPS
Orion Portfolio Solutions
Nebraska
-$134K
Name Holding Trade Value Shares
Change 		Change in
Stake
SBCM
1
Silverberg Bernstein Capital Management
New York
$202K +$203K +17,710 New
Morgan Stanley
2
Morgan Stanley
New York
$64K +$35.5K +3,100 +124%
BCI
3
Brinker Capital Investments
Pennsylvania
– -$134K -11,715 Closed
OPS
4
Orion Portfolio Solutions
Nebraska
– -$134K -11,715 Closed

PHAR Hedge Fund Activity: Q4 2023 in Review

2 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q4 2023, worth a combined $266K — down 9.9% from $296K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PHAR and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $35.5K. The largest seller was Brinker Capital Investments, exiting entirely with an estimated $134K sold.

  • 2 institutional investors held Pharming Group (PHAR) as of Q4 2023, down from 3 in Q3 2023.
  • Funds reported $266K of Pharming Group stock for Q4 2023, down 9.9% quarter-over-quarter.
  • 1 fund opened new Pharming Group positions in Q4 2023 and 2 closed out, a net change of -1 holder.
  • The largest Pharming Group buyer in Q4 2023 was Morgan Stanley, an estimated $35.5K added.
  • The largest Pharming Group seller in Q4 2023 was Brinker Capital Investments, an estimated $134K sold.

Based on aggregated 13F filings for Q4 2023.